Patents Assigned to 4SC AG
  • Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment
    Publication number: 20230201161
    Abstract: The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for the treatment of cancer.
    Type: Application
    Filed: April 17, 2019
    Publication date: June 29, 2023
    Applicant: 4SC AG
    Inventors: René BARTZ, Frank HERMANN
  • PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER
    Publication number: 20210145799
    Abstract: The invention relates to pharmaceutical combination products comprising an HD AC inhibitor, e.g. (E)-N-(2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide as well as salts and or solvents thereof and TLR7 agonist and/or TLR8 agonist for the treatment of cancer. The present invention also relates to methods of treatment of patients suffering from cancer with these pharmaceutical combination products.
    Type: Application
    Filed: April 15, 2019
    Publication date: May 20, 2021
    Applicant: 4SC AG
    Inventor: Svetlana HAMM
  • Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
    Publication number: 20210113528
    Abstract: The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with a CD137 agonist for the treatment of cancer.
    Type: Application
    Filed: March 26, 2019
    Publication date: April 22, 2021
    Applicant: 4SC AG
    Inventor: Svetlana HAMM
  • KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION
    Publication number: 20200377514
    Abstract: Disclosed are compounds within the scope of formula (II) or a salt or solvate thereof, medical uses involving them, and methods for their preparation
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Applicant: 4SC AG
    Inventors: Stefan TASLER, Ilga KRIMMELBEIN, Juergen KRAUS, Mirko ZAJA
  • KV1.3 inhibitors and their medical application
    Patent number: 10822345
    Abstract: Compounds of formula (II) or a pharmaceutically acceptable salt or solvate thereof, the medical uses thereof for diseases or medical conditions where the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial, and methods for their preparation.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: November 3, 2020
    Assignee: 4SC AG
    Inventors: Stefan Tasler, Ilga Krimmelbein, Juergen Kraus, Mirko Zaja
  • KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION
    Publication number: 20200339592
    Abstract: Compounds of formula (II) or a pharmaceutically acceptable salt or solvate thereof, the medical uses thereof for diseases or medical conditions where the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial, and methods for their preparation.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicant: 4SC AG
    Inventors: Stefan TASLER, Ilga KRIMMELBEIN, Juergen KRAUS, Mirko ZAJA
  • HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY
    Publication number: 20200261418
    Abstract: The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor as defined herein for the treatment of cancer in combination with at least one immune checkpoint modulator as defined herein.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 20, 2020
    Applicant: 4SC AG
    Inventors: Susanne DANHAUSER-RIEDL, Frank HERMANN, Roland BAUMGARTNER, Svetlana HAMM, Rene BARTZ
  • Kv1.3 inhibitors and their medical application
    Patent number: 10723743
    Abstract: Compounds of formula (II) or a pharmaceutically acceptable salt or solvate thereof, the medical uses thereof for diseases or medical conditions where the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial, and methods for their preparation.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: July 28, 2020
    Assignee: 4SC AG
    Inventors: Stefan Tasler, Ilga Krimmelbein, Juergen Kraus, Mirko Zaja
  • Method of inhibiting DYRK1B
    Patent number: 10633369
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: April 28, 2020
    Assignee: 4 SC AG
    Inventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
  • HDAC INHIBITOR IN COMBINATION WITH VEGF/VEGFR INTERACTION FOR CANCER THERAPY BASED ON PLATELET COUNT
    Publication number: 20200016118
    Abstract: The invention relates to methods, composition and uses for the of treatment of cancer selected from the group consisting of HCC, RCC, NSCLC, ovarian cancer, CCA, PTC and FTC in a subject, which comprise administering an HDAC inhibitor in combination with a compound inhibiting the VEGF/VEGFR interaction, wherein said subject is characterized in having a platelet count of about 140000 platelets/?l or higher.
    Type: Application
    Filed: April 5, 2017
    Publication date: January 16, 2020
    Applicants: 4SC AG, Yakult Honsha Co., Ltd.
    Inventors: Rolf KRAUSS, Takuya KIMURA, Masatoshi KUDO
  • KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS
    Publication number: 20190352308
    Abstract: The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein A1, A2, A3, A4, A5, A6, Y, R2 and R7 are as defined herein, and methods for producing such compounds.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 21, 2019
    Applicant: 4SC AG
    Inventors: Stefan TASLER, Ilga KRIMMELBEIN
  • Kv1.3 inhibitors and their medical applications
    Patent number: 10399991
    Abstract: The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein A1, A2, A3, A4, A5, A6, Y, R2 and R7 are as defined herein, and methods for producing such compounds.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: September 3, 2019
    Assignee: 4SC AG
    Inventors: Stefan Tasler, Ilga Krimmelbein
  • KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION
    Publication number: 20190185483
    Abstract: Compounds of formula (II) or a pharmaceutically acceptable salt or solvate thereof, the medical uses thereof for diseases or medical conditions where the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial, and methods for their preparation.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 20, 2019
    Applicant: 4SC AG
    Inventors: Stefan TASLER, Ilga KRIMMELBEIN, Juergen KRAUS, Mirko ZAJA
  • METHOD OF INHIBITING DYRK1B
    Publication number: 20180201606
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 19, 2018
    Applicant: 4 SC AG
    Inventors: Fritz ABERGER, Wolfgang GRUBER, Johann LEBAN, Hella KOHLHOF, Daniel VITT, Roland BAUMGARTNER
  • 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors
    Patent number: 10005769
    Abstract: The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R1, R2, R3, R4, RA, X1, and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: June 26, 2018
    Assignee: 4SC AG
    Inventors: Johann Leban, Mirko Zaja
  • Method of inhibiting DYRK1B
    Patent number: 9951050
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 24, 2018
    Assignee: 4 SC AG
    Inventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
  • Substituted imidazoquinolines
    Patent number: 9908880
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 6, 2018
    Assignee: 4SC AG
    Inventors: Volker Gekeler, Thomas Maier, Astrid Zimmermann, Hans-Peter Hofmann, Sanjeev A. Kulkarni, Anil P. Jagtap, Ganesh S. Chaure
  • KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION
    Publication number: 20180051034
    Abstract: Disclosed are compounds within the scope of formula (II) or a salt or solvate thereof, medical uses involving them, and methods for their preparation
    Type: Application
    Filed: March 14, 2016
    Publication date: February 22, 2018
    Applicant: 4SC AG
    Inventors: Stefan TASLER, Ilga KRIMMELBEIN, Juergen KRAUS, Mirko ZAJA
  • KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS
    Publication number: 20170369501
    Abstract: The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein A1, A2, A3, A4, A5, A6, Y, R2 and R7 are as defined herein, and methods for producing such compounds.
    Type: Application
    Filed: March 14, 2016
    Publication date: December 28, 2017
    Applicant: 4SC AG
    Inventors: Stefan TASLER, Ilga KRIMMELBEIN
  • NOVEL SUBSTITUTED IMIDAZOQUINOLINES
    Publication number: 20170029422
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Application
    Filed: September 19, 2016
    Publication date: February 2, 2017
    Applicant: 4SC AG
    Inventors: Volker GEKELER, Thomas MAIER, Astrid ZIMMERMANN, Hans-Peter HOFMANN, Sanjeev A. KULKARNI, Anil P. JAGTAP, Ganesh S. CHAURE